Skip to main content
SpringerLink
Log in

Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic Type 2 diabetes

  • Original Articles
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Background: In addition to lipid lowering, further pleotropic effects of statins have been postulated. We aimed to study if the various pleotropic effects are due indirectly to the modulation of adipocytokines. Materials and methods: We studied the effect of atorvastatin on insulin sensitivity and the plasma adiponectin and leptin concentrations. Our randomized open labeled study had 29 hyperlipidemic Type 2 diabetic patients (14 females, 15 males, mean age 60.0±2.2 yr). They were randomized into three 12-week atorvastatin intervention types. Each day patients were given either 10 mg (no.=10), 20 mg (no.=10) or 40 mg (no.=9). Evaluations were performed before and after intervention. Results: All baseline characteristics were statistically identical in the 3 groups. Drop in total cholesterol, LDL-cholesterol, and triglyceride levels were measured at the end. With 10 mg the drop was 30%, 37%, and 30%. The 20 mg group was 43%, 54%, and 34%. The 40 mg group was 42%, 51%, and 27%. Groups had no significant change of body mass index, HDL-cholesterol, and glycated hemoglobin levels. Also, levels of insulin, adiponectin, leptin, homeostasis model assessment index (HOMA) and Quantitative Insulin Sensitivity Check Index (QUICKI) stayed the same. Pooled parameters of all 29 patients showed no difference in levels of insulin, adiponectin, leptin, HOMA, and QUICKI before and after treatment. Conclusions: Atorvstatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic Type 2 diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sommeijer DW, MacGillavry MR, Meiers JC, Van Zanten AP, Reitsma PH, Ten Cate H. Anti-inflammatory and anticoagulant effects of pravastatin in patients with type 2 diabetes. Diabetes care 2004, 27: 468–73.

    Article  PubMed  CAS  Google Scholar 

  2. Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994, 89: 2519–24.

    Article  PubMed  CAS  Google Scholar 

  3. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998, 279: 1643–50.

    Article  PubMed  CAS  Google Scholar 

  4. Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 2000, 47: 648–57.

    Article  PubMed  CAS  Google Scholar 

  5. Paolisso G, Barbagallo M, Petrella G, et al. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non insulin dependent diabetic patients. Atherosclerosis 2000, 150: 121–7.

    Article  PubMed  CAS  Google Scholar 

  6. Sonmez A, Baykal Y, Kilic M, et al. Fluvastatin improves insulin resistance in nondiabetic dyslipidemic patients. Endocrine 2003, 22: 151–4.

    Article  PubMed  CAS  Google Scholar 

  7. Okada K, Maeda N, Kikuchi K, Tatsukawa M, Sawayama Y, Hayashi J.. Pravastatin improves insulin resistance in dyslipidemic patients. J Atheroscler Thromb 2005, 12: 322–9.

    Article  PubMed  CAS  Google Scholar 

  8. Sheu WHH, Shieh SM, Shen DDC, et al. Effect of pravastatin treatment on glucose, insulin, and lipoprotein metabolism in patients with hypercholesterolemia. Am Heart J 1994, 127: 331–6.

    Article  PubMed  CAS  Google Scholar 

  9. Nielsen S, Schmitz O, Møller N, et al. Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin dependent) diabetic patients with microalbuminuria. Diabetologia 1993, 36: 1079–86.

    Article  PubMed  CAS  Google Scholar 

  10. Pontrelli L, Parris W, Adeli K, Cheung RC. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism 2002, 51: 334–42.

    Article  PubMed  CAS  Google Scholar 

  11. Gannagé-Yared MH, Azar RR, Amm-Azar M, et al. Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients. Metabolism 2005, 54: 947–51

    Article  PubMed  CAS  Google Scholar 

  12. Ohrvall M, Lithell H, Johansson J, Vessby B. A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia. Metabolism 1995, 44: 212–7.

    Article  PubMed  CAS  Google Scholar 

  13. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996, 221: 286–9.

    Article  PubMed  CAS  Google Scholar 

  14. Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem 1996, 120: 803–12.

    Article  PubMed  CAS  Google Scholar 

  15. Mantzoros CS. The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med 1999, 130: 671–80.

    Article  PubMed  CAS  Google Scholar 

  16. Shamsuzzaman AS, Winnicki M, Wolk R, et al. Independent association between plasma leptin and C reactive protein in healthy human. Circulation 2004, 109: 2181–5.

    Article  PubMed  CAS  Google Scholar 

  17. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001, 7: 941–6.

    Article  PubMed  CAS  Google Scholar 

  18. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003, 278: 45021–6.

    Article  PubMed  CAS  Google Scholar 

  19. Ouchi N, Kihara A, Arita Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocytederived macrophages. Circulation 2001, 103: 1057–63.

    Article  PubMed  CAS  Google Scholar 

  20. Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003, 107: 671–4.

    Article  PubMed  CAS  Google Scholar 

  21. Kumada M, Kihara S, Ouchi N, et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004, 109: 2046–9.

    Article  PubMed  CAS  Google Scholar 

  22. Aldhahi W, Hamdy O. Adipokines, inflammation, and the endothelium in diabetes. Curr Diab Rep 2003, 3: 293–8.

    Article  PubMed  Google Scholar 

  23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412–9.

    Article  PubMed  CAS  Google Scholar 

  24. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000, 85: 2402–10.

    Article  PubMed  CAS  Google Scholar 

  25. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004, 110: 3687–92.

    Article  PubMed  CAS  Google Scholar 

  26. von Eynatten M, Schneider JG, Hadziselimovic S, et al. Adipocytokines as a novel target for the anti-inflammatory effect of atorvastatin in patients with type 2 diabetes. Diabetes Care 2005, 28: 754–5.

    Article  Google Scholar 

  27. Matsubara M, Chiba H, Maruoka S, Katayose S. Elevated serum leptin concentrations in women with compounds of multiple risk factor clustering syndrome. J Atheroscler Thromb 2000, 7: 231–7.

    Article  PubMed  CAS  Google Scholar 

  28. Konstantinides S, Schäfer K, Koschnick S, Loskutoff DJ. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for athero-thrombotic disease in obesity. J Clin Invest 2001, 108: 1533–40.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  29. Sader S, Nian M, Liu P. Leptin: a novel link between obesity, diabetes, cardiovascular risk, and ventricular hypertrophy. Circulation 2003, 108: 644–6.

    Article  PubMed  Google Scholar 

  30. Wallace AM, McMahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 2001, 104: 3052–6.

    Article  PubMed  CAS  Google Scholar 

  31. Lin LY, Liau CS, Yang WS, Su TC. Decreased serum adiponectin in adolescent and young adults with familial primary hypercholesterolemia. Lipids 2005, 40: 163–7.

    Article  PubMed  CAS  Google Scholar 

  32. Farmer JA. Pleiotropic effects of statins. Curr Atheroscler Rep 2000, 2: 208–17.

    Article  PubMed  CAS  Google Scholar 

  33. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001, 21: 1712–9.

    Article  PubMed  CAS  Google Scholar 

  34. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high risk individuals: a randomized placebo-controlled trial. Lancet 2002, 360: 7–22.

    Article  Google Scholar 

  35. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have an average or lower than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial — Lipid Lowering Arm (ASCOT — LLA): a multicenter randomized controlled trial. Lancet 2003, 361: 1149–58.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Veterans General Hospital, 386, Ta-chung 1st Rd, Kaohsiung, 813, Taiwan

    C. H. Chu MD, J. K. Lee, C. C. Lu, C. C. Sun, M. C. Wang, M. J. Chuang & M. C. Wei

  2. School of Medicine, National Yang-Ming University, Taipei

    C. H. Chu MD, J. K. Lee, H. C. Lam & C. C. Lu

  3. Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung

    H. C. Lam

  4. MeiHo Institute of Technology, Pingtung, Taiwan

    C. C. Lu

Authors
  1. C. H. Chu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. K. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. C. Lam
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. C. Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. C. Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. C. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. J. Chuang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. C. Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. H. Chu MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chu, C.H., Lee, J.K., Lam, H.C. et al. Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic Type 2 diabetes. J Endocrinol Invest 31, 42–47 (2008). https://doi.org/10.1007/BF03345565

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03345565

En]Keywords

Search

Navigation